1678. Evaluation of Sodium-Glucose Co-Transporter 2 Inhibitor Therapy and Other Potential Risk Factors for the Development of Bacteremia in Patients with Urosepsis

BACKGROUND: Though sodium-glucose co-transporter 2 (SGLT2) inhibitors have been associated with an increased risk of urinary tract infection, it is unknown whether SGLT2 inhibitors increase the risk of urinary-source bacteremia. Early recognition of bacteremia risk factors in patients with urosepsis...

Descripción completa

Detalles Bibliográficos
Autores principales: Slaten, Kelly, Harnden, Adam, Britton, Johnathyn, Covington, Elizabeth W, Johnson, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777787/
http://dx.doi.org/10.1093/ofid/ofaa439.1856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777787/
http://dx.doi.org/10.1093/ofid/ofaa439.1856

Ejemplares similares